Nitric oxide-releasing silica nanoparticle inhibition of ovarian cancer cell growth

Molecular Pharmaceutics

Volumn 7, Issue 3, 2010, Pages 775-785

  Stevens, Ellen V ^a   Carpenter, Alexis W ^b   Shin, Jae Ho ^b   Liu, Jinsong ^c   Der, Channing J ^a   Schoenfisch, Mark H ^b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b University of North Carolina at Chapel Hill   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Nanoparticle; Nitric oxide; Ovarian cancer; Ras; Silica

Indexed keywords

NANOPARTICLE; NITRIC OXIDE; PYRROLIDINE DERIVATIVE; RAS PROTEIN; SILICON DIOXIDE;

ANCHORAGE INDEPENDENT GROWTH; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; COMPARATIVE STUDY; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOSOL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; ENDOSOME; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; LYSOSOME; MOUSE; NONHUMAN; OVARY CARCINOMA; OVARY CELL; PARTICLE SIZE; PRIORITY JOURNAL;

CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; FREE RADICAL SCAVENGERS; HUMANS; MICROSCOPY, CONFOCAL; MICROSCOPY, FLUORESCENCE; NANOPARTICLES; NITRIC OXIDE; NITRIC OXIDE DONORS; OVARIAN NEOPLASMS; PYRROLIDINES; SILICON DIOXIDE;

EID: 77953259352     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp9002865     Document Type: Article

References (51)

1. Reddy, L. H. Drug delivery to tumors: Recent strategies J. Pharm. Pharmacol. 2005, 57, 1231-1242
2. Bruchez, M.; Moronne, M.; Gin, P.; Weiss, S.; Alivisatos, A. P. Semiconductor nanocrystals as fluorescent biological labels Science 1998, 281, 2013-2016
3. Nam, J. M.; Thaxton, C. C.; Mirkin, C. A. Nanoparticle-based bio-bar codes for the ultrasensitive detection of proteins Science 2003, 301, 1884-1886
4. Mahtab, R.; Rogers, J. P.; Murphy, C. J. Protein-sized quantum dot luminescence can distinguish between "straight", "bent", and "kinked" oligonucleotides J. Am. Chem. Soc. 1995, 117, 9099-9100
5. Weissleder, R.; Elizondo, G.; Wittenburg, J.; Rabito, C. A.; Bengele, H. H.; Josephson, L. Ultrasmall superparamagnetic iron oxide: Characterization of a new class of contrast agents for MR imaging Radiology 1990, 175, 489-493 (Pubitemid 20135290)
6. Zhang, L.; Gu, F. X.; Chan, J. M.; Wang, A. Z.; Langer, R. S.; Farokhzad, O. C. Nanoparticles in medicine: therapeutic applications and developments Clin. Pharmacol. Ther. 2008, 83, 761-769
7. Barbe, C.; Bartlett, J.; Linggen, K.; Finnie, K.; Qiang, L. H.; Larkin, M.; Calleja, S.; Bush, A.; Calleja, G. Silica particles: A novel drug-delivery system Adv. Mater. 2004, 16, 1959-1966
8. Stein, A.; Melde, B. J.; Schroden, R. C. Hybrid inorganic-organic mesoporous silicates-nanoscopic reactors coming of age Adv. Mater. 2000, 12, 1403-1419
9. Brunner, T. J.; Wick, P.; Manser, P.; Spohn, P.; Grass, R. N.; Limbach, L. K.; Bruinink, A.; Stark, W. J. In vitro cytotoxicity of oxide nanoparticles: Comparison to asbestos, silica, and the effect of particle solubility Environ. Sci. Technol. 2006, 40, 4374-4381
10. Sayari, A.; Hamoudi, S. Periodic mesoporous silica-based organic-inorganic nanocomposite materials Chem. Mater. 2001, 13, 3151-3168
11. Cho, K.; Wang, X.; Nie, S.; Chen, Z. G.; Shin, D. M. Therapeutic nanoparticles for drug delivery in cancer Clin. Cancer Res. 2008, 14, 1310-1316
12. Byrne, J. D.; Betancourt, T.; Brannon-Peppas, L. Active targeting schemes for nanoparticle systems in cancer therapeutics Adv. Drug Delivery Rev. 2008, 60, 1615-1626
13. Bonavida, B.; Khineche, S.; Huerta-Yepez, S.; Garban, H. Therapeutic potential of nitric oxide in cancer Drug Resist. Updates 2006, 9, 157-173
14. Miller, M. R.; Megson, I. L. Recent developments in nitric oxide donor drugs Br. J. Pharmacol. 2007, 151, 305-321
15. Huerta, S.; Chilka, S.; Bonavida, B. Nitric oxide donors: novel cancer therapeutics (review) Int. J. Oncol. 2008, 33, 909-927
16. Albina, J. E.; Reichner, J. S. Role of nitric oxide in mediation of macrophage cytotoxicity and apoptosis Cancer Metastasis Rev. 1998, 17, 19-53
17. Fukumura, D.; Kashiwagi, S.; Jain, R. K. The role of nitric oxide in tumour progression Nat. Rev. Cancer 2006, 6, 521-534
18. Lo, H.-W.; Hung, M.-C. Nuclear EGFR signaling network in cancers: Linking EGFR pathway to cell cycle progression, nitric oxide pathway and patient survival Br. J. Cancer 2006, 94, 184-188
19. Mimeault, M.; Jouy, N.; Depreux, P.; Henichart, J.-P. Synergistic antiproliferative and apoptotic effects induced by mixed epidermal growth factor receptor inhibitor ZD1839 and nitric oxide donor in human prostatic cancer cell lines Prostate 2005, 62, 187-199
20. Pervin, S.; Singh, R.; Chaudhuri, G. Nitric oxide-induced cytostasis and cell cycle arrest of a human breast cancer cell line (MDA-MB-231): Potential role of cyclin D1 Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 3583-3588
21. Jia, L.; Schweizer, J.; Wang, Y.; Cerna, C.; Wong, H.; Revilla, M. Effect of nitric oxide on cytotoxicity of Taxol: Enhanced Taxol transcellular permeability Biochem. Pharmacol. 2003, 66, 2193-2199
22. Adami, A.; Crivellente, F.; De Prati, A. C.; Cavalieri, E.; Cuzzolin, L.; Tommasi, M.; Suzuki, H.; Benoni, G. Biotransformation and cytotoxic properties of NO-donors on MCF7 and U251 cell lines Life Sci. 1998, 63, 2097-2105
23. Huerta, S.; Baay-Guzman, G.; Gonzalez-Bonilla, C. R.; Livingston, E. H.; Huerta-Yepez, S.; Bonavida, B. In vitro and in vivo sensitization of SW620 metastatic colon cancer cells to CDDP-induced apoptosis by the nitric oxide donor DETANONOate: Involvement of AIF Nitric Oxide 2009, 20, 182-194
24. Saavedra, J. E.; Srinivasan, A.; Buzard, G. S.; Davies, K. M.; Waterhouse, D. J.; Inami, K.; Wilde, T. C.; Citro, M. L.; Cuellar, M.; Deschamps, J. R.; Parrish, D.; Shami, P. J.; Findlay, V. J.; Townsend, D. M.; Tew, K. D.; Singh, S.; Jia, L.; Ji, X.; Keefer, L. K. PABA/NO as an anticancer lead: Analogue synthesis, structure revision, solution chemistry, reactivity toward glutathione, and in vitro activity J. Med. Chem. 2006, 49, 1157-1164
25. Bratasz, A.; Weir, N. M.; Parinandi, N. L.; Zweier, J. L.; Sridhar, R.; Ignarro, L. J.; Kuppusamy, P. Reversal to cisplatin sensitivity in recurrent human ovarian cancer cells by NCX-4016, a nitro derivative of aspirin Proc. Natl. Acad. Sci. U.S.A. 2006, 103, 3914-3919
26. Shin, J. H.; Metzger, S. K.; Schoenfisch, M. H. Synthesis of nitric oxide-releasing silica nanoparticles J. Am. Chem. Soc. 2007, 129, 4612-4619
27. Shin, J. H.; Schoenfisch, M. H. Inorganic/organic hybrid silica nanoparticles as a nitric oxide delivery scaffold Chem. Mater. 2008, 20, 239-249
28. Liu, J.; Yang, G.; Thompson-Lanza, J. A.; Glassman, A.; Hayes, K.; Patterson, A.; Marquez, R. T.; Auersperg, N.; Yu, Y.; Hahn, W. C.; Mills, G. B.; Bast, R. C., Jr. A genetically defined model for human ovarian cancer Cancer Res. 2004, 64, 1655-1663
29. Saavedra, J. E.; Billiar, T. R.; Williams, D. L.; Kim, Y. M.; Watkins, S. C.; Keefer, L. K. Targeting nitric oxide (NO) delivery in vivo. Design of a liver-selective NO donor prodrug that blocks tumor necrosis factor-alpha-induced apoptosis and toxicity in the liver J. Med. Chem. 1997, 40, 1947-1954
30. Keefer, L. K.; Nims, R. W.; Davies, K. M.; Wink, D. A. NONOates" (1-substituted diazen-1-ium-1,2-diolates) as nitric oxide donors: convenient nitric oxide dosage forms Methods Enzymol. 1996, 268, 281-293
31. Stevens, E. V.; Nishizuka, S.; Antony, S.; Reimers, M.; Varma, S.; Young, L.; Munson, P. J.; Weinstein, J. N.; Kohn, E. C.; Pommier, Y. Predicting cisplatin and trabectedin drug sensitivity in ovarian and colon cancers Mol. Cancer Ther. 2008, 7, 10-18
32. Polizzi, M. A.; Stasko, N. A.; Schoenfisch, M. Water-soluble nitric oxide-releasing gold nanoparticles Langmuir 2007, 23, 4938-4943 (Pubitemid 46731975)
33. Hong, S.; Bielinska, A. U.; Mecke, A.; Keszler, B.; Beals, J. L.; Shi, X.; Balogh, L.; Orr, B. G.; Baker, J. R., Jr.; Banaszak Holl, M. M. Interaction of poly(amidoamine) dendrimers with supported lipid bilayers and cells: hole formation and the relation to transport Bioconjugate Chem. 2004, 15, 774-782
34. Sun, W.; Fang, N.; Trewyn, B. G.; Tsunoda, M.; Slowing, I. I.; Lin, V. S.; Yeung, E. S. Endocytosis of a single mesoporous silica nanoparticle into a human lung cancer cell observed by differential interference contrast microscopy Anal. Bioanal. Chem. 2008, 391, 2119-2125
35. Rosetti, M.; Tesei, A.; Ulivi, P.; Fabbri, F.; Vannini, I.; Brigliadori, G.; Amadori, D.; Bolla, M.; Zoli, W. Molecular characterization of cytotoxic and resistance mechanisms induced by NCX 4040, a novel NO-NSAID, in pancreatic cancer cell lines Apoptosis 2006, 11, 1321-1330
36. Ouyang, N.; Williams, J. L.; Rigas, B. NO-donating aspirin inhibits angiogenesis by suppressing VEGF expression in HT-29 human colon cancer mouse xenografts Carcinogenesis 2008, 29, 1794-1798
37. Kojima, H.; Nakatsubo, N.; Kikuchi, K.; Kawahara, S.; Kirino, Y.; Nagoshi, H.; Hirata, Y.; Nagano, T. Detection and imaging of nitric oxide with novel fluorescent indicators: diaminofluoresceins Anal. Chem. 1998, 70, 2446-2453
38. Shao, C.; Stewart, V.; Folkard, M.; Michael, B. D.; Prise, K. M. Nitric oxide-mediated signaling in the bystander response of individually targeted glioma cells Cancer Res. 2003, 63, 8437-8442
39. Luo, Y.; Prestwich, G. D. Cancer-targeted polymeric drugs Curr. Cancer Drug Targets 2002, 2, 209-226
40. Stasko, N. A.; Johnson, C. B.; Schoenfisch, M. H.; Johnson, T. A.; Holmuhamedov, E. L. Cytotoxicity of polypropylenimine dendrimer conjugates on cultured endothelial cells Biomacromolecules 2007, 8, 3853-3859
41. Maeda, H.; Wu, J.; Sawa, T.; Matsumura, Y.; Hori, K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review J. Controlled Release 2000, 65, 271-284
42. Leuschner, C.; Kumar, C. Nanoparticles for cancer drug delivery. In Nanofabrication towards Biomedical Applications: Techniques, Tools, Applications, and Impact, 1st ed.; Kumar, C. S. S. R.; Hormes, J.; Leuschner, C., Eds.; Wiley-VCH Verlag GmbH & Co.: Weinheim, Germany, 2005; pp 289 - 315.
43. Slowing, I.; Trewyn, B. G.; Lin, V. S. Effect of surface functionalization of MCM-41-type mesoporous silica nanoparticles on the endocytosis by human cancer cells J. Am. Chem. Soc. 2006, 128, 14792-14793
44. Lu, J.; Liong, M.; Zink, J. I.; Tamanoi, F. Mesoporous silica nanoparticles as a delivery system for hydrophobic anticancer drugs Small 2007, 3, 1341-1346
45. Rejman, J.; Oberle, V.; Zuhorn, I. S.; Hoekstra, D. Size-dependent internalization of particles via the pathways of clathrin- and caveolae-mediated endocytosis Biochem. J. 2004, 377, 159-169
46. Boyd, C. S.; Cadenas, E. Nitric oxide and cell signaling pathways in mitochondrial-dependent apoptosis Biol. Chem. 2002, 383, 411-423
47. Selvendiran, K.; Bratasz, A.; Tong, L.; Ignarro, L. J.; Kuppusamy, P. NCX-4016, a nitro-derivative of aspirin, inhibits EGFR and STAT3 signaling and modulates Bcl-2 proteins in cisplatin-resistant human ovarian cancer cells and xenografts Cell Cycle 2008, 7, 81-88
48. Oberdorster, G.; Oberdorster, E.; Oberdorster, J. Nanotoxicology: an emerging discipline evolving from studies of ultrafine particles Environ. Health Perspect. 2005, 113, 823-839
49. Yu, K.; Grabinski, C.; Schrand, A.; Murdock, R.; Wang, W.; Gu, B.; Schlager, J.; Hussain, S. Toxicity of amorphous silica nanoparticles in mouse keratinocytes J. Nanopart. Res. 2009, 11, 15-24
50. He, X.; Nie, H.; Wang, K.; Tan, W.; Wu, X.; Zhang, P. In Vivo Study of Biodistribution and Urinary Excretion of Surface-Modified Silica Nanoparticles Anal. Chem. 2008, 80, 9597-9603
51. Ryan, S. M.; Mantovani, G.; Wang, X.; Haddleton, D. M.; Brayden, D. J. Advances in PEGylation of important biotech molecules: delivery aspects Expert Opin. Drug Delivery 2008, 5, 371-383